Intragraft CD11b+IDO+ cells mediate cardiac allograft tolerance by ecdi-fixed donor splenocyte infusions

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 2920-2929

  Chen, G ^a,b   Kheradmand, T ^a   Bryant, J ^a   Wang, S ^a,c   Tasch, J ^a   Wang, J J ^a   Zhang, Z ^a   Luo, X ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

3 dioxygenase); Cardiac transplantation; ECDI (ethylene carbodiimide); Foxp3+ regulatory T cells; Gr1+ monocytes; IDO (indoleamine 2; IL 10 (interleukin 10); IL 13 (interleukin 13); rapamycin; tolerance

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; CD11B ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 13; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR LYMPHOCYTE INFUSION; ENZYME INHIBITION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOLOGY; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD11B; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; ISOANTIGENS; MALE; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; SIROLIMUS; SPLEEN; STATISTICS, NONPARAMETRIC; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84868195029     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04203.x     Document Type: Article

References (45)

1. Lechler RI, Sykes M, Thomson AW, Turka LA,. Organ transplantation-How much of the promise has been realized? Nat Med 2005; 11: 605-613.
2. Dugast AS, Haudebourg T, Coulon F, et al,. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898-7906.
3. Garcia MR, Ledgerwood L, Yang Y, et al,. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest 2010; 120: 2486-2496.
4. Jia W, Jackson-Cook C, Graf MR,. Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J Neuroimmunol 2010; 223: 20-30.
5. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P,. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-5505.
6. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V,. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
7. Baban B, Chandler PR, Johnson BA 3rd, et al,. Physiologic control of IDO competence in splenic dendritic cells. J Immunol 2011; 187: 2329-2335.
8. Soliman H, Mediavilla-Varela M, Antonia S,. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J 2010; 16: 354-359.
9. Jurgens B, Hainz U, Fuchs D, Felzmann T, Heitger A,. Interferon-gamma- triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009; 114: 3235-3243.
10. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H,. Regulatory T cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
11. Li XL, Menoret S, Bezie S, et al,. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. J Immunol 2010; 185: 823-833.
12. Guillonneau C, Hill M, Hubert FX, et al,. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 1096-1106.
13. Turley DM, Miller SD,. Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol 2007; 178: 2212-2220.
14. Miller SD, Turley DM, Podojil JR,. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol 2007; 7: 665-677.
15. Kennedy MK, Tan LJ, Dal Canto MC, Miller SD,. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J Immunol 1990; 145: 117-126.
16. Fife BT, Guleria I, Gubbels Bupp M, et al,. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 2006; 203: 2737-2347.
17. Luo X, Pothoven KL, McCarthy D, et al,. ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A 2008; 105: 14527-14532.
18. Kheradmand T, Wang S, Bryant J, et al,. Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. J Immunol 2012; 189: 804-812.
19. Kaneko K, Morelli AE, Wang Z, Thomson AW,. Alloantigen presentation by ethylcarbodiimide-treated dendritic cells induces T cell hyporesponsiveness, and prolongs organ graft survival. Clin Immunol 2003; 108: 190-198.
20. Zhang Z, Zhu L, Quan D, et al,. Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation 1996; 62: 1267-1272.
21. Getts DR, Turley DM, Smith CE, et al,. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol 2011; 187: 2405-2417.
22. Chen W,. IDO: More than an enzyme. Nat Immunol 2011; 12: 809-811.
23. Blaschitz A, Gauster M, Fuchs D, et al,. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS One 2011; 6: e21774.
24. Ibana JA, Belland RJ, Zea AH, et al,. Inhibition of indoleamine 2,3-dioxygenase activity by levo-1-methyl tryptophan blocks gamma interferon-induced Chlamydia trachomatis persistence in human epithelial cells. Infect Immun 2011; 79: 4425-4437.
25. Oh GS, Pae HO, Choi BM, et al,. 3-Hydroxyanthranilic acid, one of metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses inducible nitric oxide synthase expression by enhancing heme oxygenase-1 expression. Biochem Biophys Res Commun 2004; 320: 1156-1162.
26. Ohtaki H, Ito H, Ando K, et al,. Interaction between LPS-induced NO production and IDO activity in mouse peritoneal cells in the presence of activated Valpha14 NKT cells. Biochem Biophys Res Commun 2009; 389: 229-234.
27. Samelson-Jones BJ, Yeh SR,. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry 2006; 45: 8527-8538.
28. Sucher R, Fischler K, Oberhuber R, et al,. IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. J Immunol 2012; 188: 37-46.
29. Thebault P, Condamine T, Heslan M, et al,. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by induction of IDO in endothelial cells. Am J Transplant 2007; 7: 2472-2482.
30. Gehrie E, Van der Touw W, Bromberg JS, Ochando JC,. Plasmacytoid dendritic cells in tolerance. Methods Mol Biol 2011; 677: 127-147.
31. Trabanelli S, Ocadlikova D, Evangelisti C, Parisi S, Curti A,. Induction of regulatory T Cells by dendritic cells through indoleamine 2,3-dioxygenase: A potent mechanism of acquired peripheral tolerance. Curr Med Chem 2011; 18: 2234-2239.
32. Serafini P, Mgebroff S, Noonan K, Borrello I,. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008; 68: 5439-5449.
33. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F,. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011; 117: 6532-6541.
34. Pan PY, Ma G, Weber KJ, et al,. Immune stimulatory receptor CD40 is required for T cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70: 99-108.
35. Quintana FJ, Basso AS, Iglesias AH, et al,. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453: 65-71.
36. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA,. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185: 3190-3198.
37. Gandhi R, Kumar D, Burns EJ, et al,. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010; 11: 846-853.
38. Hauben E, Gregori S, Draghici E, et al,. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 2008; 112: 1214-1222.
39. Wu HY, Quintana FJ, da Cunha AP, et al,. In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS One 2011; 6: e23618.
40. Apetoh L, Quintana FJ, Pot C, et al,. The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010; 11: 854-861.
41. Nguyen NT, Kimura A, Nakahama T, et al,. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 2010; 107: 19961-19966.
42. Inoue Y, Konieczny BT, Wagener ME, McKenzie AN, Lakkis FG,. Failure to induce neonatal tolerance in mice that lack both IL-4 and IL-13 but not in those that lack IL-4 alone. J Immunol 2001; 167: 1125-1128.
43. Davidson C, Verma ND, Robinson CM, et al,. IL-13 prolongs allograft survival: association with inhibition of macrophage cytokine activation. Transpl Immunol 2007; 17: 178-186.
44. Gorczynski RM, Chen Z, He W, et al,. Expression of a CD200 transgene is necessary for induction but not maintenance of tolerance to cardiac and skin allografts. J Immunol 2009; 183: 1560-1568.
45. Ke B, Shen XD, Zhai Y, et al,. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 2002; 13: 1845-1857.